Considering that the 2011 United Nations political declaration on non-communicable diseases calls for member states to promote the use of affordable medicines, including generics, for palliative care; 1 Considering the World Health Organization's recommendation that essential medicines should be available to patients at all times and at a price the individual and the community can afford; 2
Recognizing that morphine is the only strong opioid analgesic included in the WHO Model List of Essential Medicines; 3
In the light of the available scientific evidence that immediate release oral morphine is both safe and effective as first-line treatment for severe pain, 4;5 Finding that immediate release oral morphine is less expensive for patients than sustained release morphine and most other strong opioid formulations; 6 Aware that in many institutions, particularly in low and low-middle income countries, immediate release oral morphine is not available, while opioid formulations that are more expensive (or more difficult to use, such as injectable morphine) are available;
Considering that the high cost of opioids hinders access to treatment to the vast majority of patients in many low and low-middle income countries, resulting in millions of patients suffering needlessly with untreated pain;
Recognizing that the low profit margin typically realized from selling immediate release oral morphine is often made worse by the additional costs of unnecessarily burdensome regulatory requirements, which may further deter the pharmaceutical industry from supplying immediate release morphine, DECLARE that denial of adequate pain treatment to significant numbers of patients violates the right to the highest attainable standard of physical and mental health, as articulated in article 12 of the International Covenant on Economic, Social and Cultural Rights, 7 and may violate the prohibition of cruel, inhuman, or degrading treatment 8 as articulated in article 7 of the International Covenant on Civil and Political Rights; 9 and DECLARE that the exclusive availability of sustained release morphine and other expensive or injectable opioid formulations hinders access to an essential health service, leading to poor clinical and public health practice.
WE CALL UPON GOVERNMENTS, PHARMACEUTICAL INDUSTRY AND HEALTH CARE
INSTITUTIONS to guarantee the accessibility of immediate release oral morphine to patients in need at a cost that the individual and community can afford. In particular:
• Governments should ensure that immediate release oral morphine is always available in public healthcare institutions before other more expensive opioid formulations become available. Where more expensive or injectable opioid formulations are already available and immediate release oral morphine is not, they should take immediate steps to ensure that it becomes available.
• Governments should work collaboratively with private healthcare institutions and the pharmaceutical industry to ensure the widest possible availability and accessibility of immediate release oral morphine in the private healthcare system.
• Governments should minimize the impact of regulatory requirements on the manufacturing, importation, exportation and distribution of opioid analgesics and work with the pharmaceutical industry to facilitate the availability of immediate release oral morphine.
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